Gou Yi, Miao Dandan, Zhou Min, Wang Lijuan, Zhou Hongyu, Su Gaoxing
Jiangsu Province Key Laboratory of Inflammation and Molecular Drug Targets, School of Pharmacy, Nantong University, Nantong, China.
Guangzhou Key Laboratory of Environmental Exposure and Health and Guangdong Key Laboratory of Environmental Pollution and Health, School of Environment, Jinan University, Guangzhou, China.
Front Pharmacol. 2018 Apr 27;9:421. doi: 10.3389/fphar.2018.00421. eCollection 2018.
Over the past decade, more interests have been aroused in engineering protein-based nanoformulations for cancer treatment. This excitement originates from the success of FDA approved Abraxane (Albumin-based paclitaxel nanoparticles) in 2005. The new generation of biocompatible endogenous protein-based nanoformulations is currently constructed through delivering cancer therapeutic and diagnostic agents simultaneously, as named potential theranostics. Protein nanoformulations are commonly incorporated with dyes, contrast agents, drug payloads or inorganic nanoclusters, serving as imaging-guided combinatorial cancer therapeutics. Employing the nature identity of proteins, the theranostics, escape the clearance by reticuloendothelial cells and have a long blood circulation time. The nanoscale sizet allows them to be penetrated deeply into tumor tissues. In addition, stimuli release and targeted molecules are incorporated to improve the delivery efficiency. The ongoing advancement of protein-based nanoformulations for cancer theranostics in recent 5 years is reviewed in this paper. Fine-designed nanoformulations based on albumin, ferritin, gelatin, and transferrin are highlighted from the literature. Finally, the current challenges are identified in translating protein-based nanoformulations from laboratory to clinical trials.
在过去十年中，工程化基于蛋白质的纳米制剂用于癌症治疗引起了更多关注。这种热潮源于2005年美国食品药品监督管理局（FDA）批准的艾力雅（基于白蛋白的紫杉醇纳米颗粒）的成功。新一代具有生物相容性的内源性基于蛋白质的纳米制剂目前是通过同时递送癌症治疗和诊断剂构建而成的，被称为潜在的诊疗试剂。蛋白质纳米制剂通常与染料、造影剂、药物载体或无机纳米团簇结合，用作成像引导的联合癌症治疗方法。利用蛋白质的天然特性，这些诊疗试剂能够逃避网状内皮细胞的清除，具有较长的血液循环时间。纳米级尺寸使它们能够深入渗透到肿瘤组织中。此外，还引入了刺激释放和靶向分子以提高递送效率。本文综述了近5年来基于蛋白质的纳米制剂用于癌症诊疗的研究进展。从文献中突出了基于白蛋白、铁蛋白、明胶和转铁蛋白精心精心设计的纳米制剂。最后，确定了将基于蛋白质的纳米制剂从实验室转化为临床试验目前面临的挑战。
